Compassionate Use and Expanded Access: What They Mean for Tigilanol Tiglate Patients
Before a drug achieves full approval, compassionate use and expanded access programmes can provide a legal pathway for patients who have no other options. Here's how they apply to tigilanol tiglate.
What Compassionate Use Actually Means
The phrase "compassionate use" sounds informal — as if access to an unapproved drug is granted based on sympathy alone. In regulatory reality, it is a carefully defined legal framework that allows patients with serious or life-threatening conditions to access investigational drugs outside of a clinical trial, when no comparable alternative exists.[1]
Both the FDA (which calls its programme Expanded Access) and the EMA (which uses the term Compassionate Use) have established procedures for granting this access. For a compound like tigilanol tiglate — approved for veterinary oncology, actively in human Phase I/II trials, and showing significant preliminary efficacy — these pathways are directly relevant to patients who cannot wait for full approval.
The FDA Expanded Access Framework
The FDA's Expanded Access programme covers three types of access: individual patient (including emergency access), intermediate-size patient populations, and widespread treatment use. For most cancer patients seeking tigilanol tiglate, the individual patient pathway is the most relevant.[2]
To qualify, a patient must have a serious or life-threatening condition, there must be no comparable approved alternative, and the potential benefit must outweigh the risks. The drug's sponsor — in this case QBiotics — must agree to provide the compound, and the treating physician must submit a formal application.[3]
The FDA typically responds to emergency requests within 24 hours and non-emergency individual requests within 30 days. This is not a guaranteed path, but it is a legitimate and frequently used one: the FDA receives thousands of expanded access requests each year and approves the vast majority.
The EMA Compassionate Use Programme
The EMA's compassionate use framework operates slightly differently. Under Article 83 of Regulation (EC) No 726/2004, member states can make medicinal products available on a compassionate use basis when they are subject to a marketing authorisation application or undergoing clinical trials.[4]
Importantly, compassionate use under the EMA framework is organised at the national level — each EU member state manages its own programme. A patient in Germany, France, or Sweden will need to apply through their national regulatory authority rather than directly to the EMA itself. The EMA provides scientific guidance and coordinates recommendations, but implementation is national.
Given that tigilanol tiglate has already received EMA marketing authorisation for veterinary use (Stelfonta), the compound has an established safety profile within the European regulatory system — which meaningfully strengthens the case for compassionate use applications in human oncology.
What Patients and Physicians Need to Know
The practical reality of compassionate use is that it requires a physician willing to take on the administrative burden of application and ongoing safety reporting. It is not a path patients can navigate alone — it requires an engaged oncologist who believes the potential benefit justifies the effort.[5]
For tigilanol tiglate specifically, the existing Phase I and Phase II trial data — covering head and neck squamous cell carcinoma and other solid tumour types — provides the safety and efficacy foundation that regulators require to consider expanded access requests favourably.
The Bigger Picture: Access as an Ethical Imperative
The tension between regulatory caution and patient urgency is one of the defining ethical challenges of modern oncology. Compassionate use programmes represent the regulatory system's attempt to resolve that tension — acknowledging that for patients with no remaining approved options, the calculus of risk is fundamentally different.[6]
Tigilanol tiglate's journey through veterinary approval, Orphan Drug Designation, and human clinical trials represents exactly the kind of development trajectory that regulatory bodies designed expanded access for. The compound is not experimental in the sense of unknown — it is investigational in the sense of still being formally evaluated for specific human indications. That distinction matters when patients and physicians are weighing their options.
References
- 1–2. FDA Expanded Access (Compassionate Use) Programme. View source ↗
- 3. QBiotics — tigilanol tiglate clinical development programme. View source ↗
- 4. EMA Stelfonta EPAR — veterinary authorisation background. View source ↗
- 5. ClinicalTrials.gov — active tigilanol tiglate trials. View source ↗
- 6. Boyle GM et al. "Intratumoural injection of EBC-46 rapidly ablates tumours." PLOS ONE. 2014. View source ↗
